why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat

Course: BTK Inhibition in Lymphomas: A Focus on Frontline Therapy for DLBCL

CME Credits: 0.00

Released: 2025-01-28

As ongoing advances continue to change the treatment landscape for difficult?to-treat diffuse large B?cell lymphoma (DLBCL), it is imperative that clinicians stay up to date with the most recent safety and efficacy data for emerging treatment options such as BTK inhibitors and when to consider these therapies for their patients. To help realize the potential of BTK inhibitors in DLBCL, join a panel of DLBCL experts discuss incorporating these therapies in the frontline setting, management of associated side effects, and personalization of treatment plans. Panelists will also discuss the insights from a practice patterns survey of community-based clinicians that manage their patients with DLBCL with BTK inhibitors.


View Full Course